Sutro Works Toward A Better Ovarian Cancer ADC

Readies Next Asset For The Clinic

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

• Source: Shutterstock

Sutro Biopharma, Inc. chose to focus its cell-free protein synthesis technology platform on antibody-drug conjugates (ADCs) long before ADCs were elevated to high-value status in recent years, and the company has used business development strategically to raise funding for its wholly owned development programs and to advance its XpressCF platform. Now, its lead ADC candidate luveltamab tazevibulin (luvelta) is in a pivotal trial to see if Sutro can deliver a better ovarian cancer option.

Key Takeaways

Sutro has taken lead product candidate luvelta into a pivotal trial in ovarian cancer in an increasingly competitive space – FRα-targeting ADCs.
The company...

Scrip spoke with CEO Bill Newell at the recent BIO International Convention about luvelta’s ongoing Phase II/III REFRαME-01 clinical trial, which is testing Sutro’s folate receptor alpha (FRα)-targeting ADC in...